Covid-19 vaccine developer AstraZeneca agrees to buy rare disease firm Alexion for $39 billion
Leading Covid-19 vaccine developer AstraZeneca agreed on Saturday to buy Boston pharmaceutical firm Alexion for $39 billion.
Full Article
Covid-19 vaccine developer AstraZeneca agrees to buy rare disease firm Alexion for $39 billion
Upworthy
0 shares
1 views
You might like
Related news coverage
Hoarding The Jabs: The Inequalities Of Vaccine Distribution – OpEd
Eurasia Review
Public health is no excuse to keep business and patriotism at bay. Not a very humanitarian sentiment, but then again, healing the..
-
COVID-19 dominates 2020 for biotech sector … and everyone else
Proactive Investors
-
US stocks end mixed session as investors fret additional COVID-19 restrictions
Proactive Investors
-
US stocks higher midday amid vaccine rollout and hopes for COVID aid package
Proactive Investors
-
UK's Astrazeneca buying US Biotech firm Alexion for 39 Billion dollars to expand in immunology
Mid-Day
Advertisement
More coverage
AstraZeneca buying drug developer Alexion for $39 billion
LONDON (AP) — Pharmaceutical company AstraZeneca says it is buying U.S. drug developer Alexion in a deal worth $39..
SeattlePI.com